The Filing Desk

MaxCyte vs Rapid Micro Biosystems

MaxCyte MXCT · Rapid Micro Biosystems RPID · Life Sciences Tools & Services

Rapid Micro Biosystems reported revenue of $34 million in fiscal 2025, about the same as MaxCyte's $33 million in fiscal 2025. MaxCyte's revenue fell 14.5% in its latest year, and Rapid Micro Biosystems' grew 19.7%. MaxCyte had an operating margin of -157.1%, against -141.1% at Rapid Micro Biosystems. Free cash flow was −$36 million at MaxCyte and −$32 million at Rapid Micro Biosystems.

Side by side

MaxCyteRapid Micro Biosystems
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$33M$34M
Revenue growth−14.5%19.7%
Revenue growth a year, last 5 years4.7%15.9%
Gross margin81.2%—
Operating margin−157.1%−141.1%
Net margin−135.1%−140.3%
Free cash flow−$36M−$32M
Free cash flow margin−109.5%−95.0%
Return on capital—−192.8%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.5%2.5%
Last close$1.28$0.74
P/E at the last close——
Insider trades, last 12 monthsbought $120,780, sold $8,316sold $1.1 million
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MaxCyteRapid Micro Biosystems
Operating margin
Percent of revenue
MaxCyteRapid Micro Biosystems
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MaxCyteRapid Micro Biosystems

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MaxCyte and Rapid Micro Biosystems pages.